

Mark Steven Freedman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7782093/publications.pdf>

Version: 2024-02-01

13
papers

3,239
citations

1162367

8
h-index

1125271

13
g-index

15
all docs

15
docs citations

15
times ranked

4580
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.5	2,344
2	Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. <i>JAMA Neurology</i> , 2014, 71, 306.	4.5	402
3	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , 2018, 17, 405-415.	4.9	238
4	Sodium intake and multiple sclerosis activity and progression in <scp>BENEFIT</scp>. <i>Annals of Neurology</i> , 2017, 82, 20-29.	2.8	80
5	Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMPO) of oral teriflunomide in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1625-1632.	1.4	75
6	A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td	2.1	40
7	Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 159-167.	0.3	20
8	Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents. <i>American Journal of Neuroradiology</i> , 2018, 39, 1597-1603.	1.2	18
9	Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2022, 99, .	1.5	6
10	Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-9.	0.3	5
11	Is there a safe time to discontinue therapy in MS?. <i>Nature Reviews Neurology</i> , 2017, 13, 10-11.	4.9	4
12	Clinical and MRI efficacy of sc IFN Î²-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. <i>Journal of Neurology</i> , 2020, 267, 64-75.	1.8	4
13	Physical Activity Together for People With Multiple Sclerosis and Their Care Partners: Protocol for a Feasibility Randomized Controlled Trial of a Dyadic Intervention. <i>JMIR Research Protocols</i> , 2021, 10, e18410.	0.5	3